Treatment of osteopenia

Reviews in Endocrine and Metabolic Disorders

Volumn 13, Issue 3, 2012, Pages 209-223

  Eriksen, Erik Fink ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bisphosphonates; DXA; FRAX; Hormone replacement therapy; Osteopenia; Osteoporosis; Parathyroid hormone; SERM

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; DENOSUMAB; IBANDRONIC ACID; LASOFOXIFENE; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM RANELATE; TAMOXIFEN; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN THERAPY; ARTHRALGIA; BONE DENSITY; BONE MASS; BONE METASTASIS; BONE TURNOVER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; EXERCISE; FALLING; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOGONADISM; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; MYALGIA; NAUSEA; NONHUMAN; NUTRITION; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT IDENTIFICATION; POSTMENOPAUSE; REVIEW; RHINITIS; RISK ASSESSMENT; SMOKING CESSATION; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ACCIDENTAL FALLS; AGED; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; HUMANS; LIFE STYLE; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84865455225     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9187-z     Document Type: Review

References (120)

1. ES Siris YT Chen TA Abbott E Barrett-Connor PD Miller LE Wehren ML Berger 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 1108 12 15159268
2. KE Ensrud DE Thompson JA Cauley MC Nevitt DM Kado MC Hochberg AC Santora DM Black 2000 Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture intervention trial research group.[see comment] J Am Geriatr Soc 48 241 9 10733048 1:STN:280:DC%2BD3c7psFWrtA%3D%3D
3. O Johnell JA Kanis A Oden I Sernbo I Redlund-Johnell C Petterson C De Laet B Jonsson 2004 Mortality after osteoporotic fractures Osteoporos Int 15 38 42 14593451 1:STN:280:DC%2BD2c%2FitlOhsw%3D%3D
4. SA Quandt DE Thompson DL Schneider MC Nevitt DM Black Fracture Intervention Trial Research Group 2005 Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the fracture intervention trial Mayo Clinic Proc 80 343 9 1:CAS:528:DC%2BD2MXis1SltL0%3D
5. DM Black S Boonen J Cauley P Delmas R Eastell I Reid T Rosario-Jansen J Caminis J Zhang H Hu S Cummings 2006 Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial Arthritis Rheum 54 S305
6. JA Riancho 1999 Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate Rev Clin Esp 199 349 55 10432808 1:STN:280:DyaK1MzmtFeksQ%3D%3D
7. O Lamy MA Krieg 2004 Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach Praxis (Bern 1994) 93 399 405 1:STN:280:DC%2BD2c7mvVSisQ%3D%3D
8. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.[see comment] JAMA 280 2077 82 9875874 1:CAS:528:DyaK1MXjsVWruw%3D%3D
9. National osteoporosis Foundation-Clinicans guide to prevention and treatment of osteoporosis. www.nof.org/professionals/Clinicians-Guide.htm [serial online] Available at: www.nof.org/professionals/Clinicians-Guide.htm.
10. Lyles KW, Colon-Emeric C, Magaziner J, Adachi J, Pieper CF, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. The effect of once yearly zoledronic acid on new fractures and mortality after hip fracture. 2007; In press.
11. S van Helden AC van Geel PP Geusens A Kessels AC Nieuwenhuijzen Kruseman PR Brink 2008 Bone and fall-related fracture risks in women and men with a recent clinical fracture J Bone Joint Surg Am 90 241 8 18245581
12. JA Kanis EV McCloskey H Johansson O Strom F Borgstrom A Oden 2008 Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK Osteoporos Int 19 1395 408 18751937 1:STN:280: DC%2BD1crnvFelug%3D%3D
13. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449-58.
14. TA van Geel S van Helden PP Geusens B Winkens GJ Dinant 2009 Clinical subsequent fractures cluster in time after first fractures Ann Rheum Dis 68 99 102 18677009
15. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 21 19190316 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D
16. T Chevalley P Hoffmeyer JP Bonjour R Rizzoli 2002 An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture Osteoporos Int 13 450 5 12107657 1:STN:280:DC%2BD38zmvFemsw%3D%3D
17. P Sambrook C Cooper 2006 Osteoporosis Lancet 367 2010 8 16782492 1:CAS:528:DC%2BD28XlvFGltLs%3D
18. WF Lems 2007 Clinical relevance of vertebral fractures Ann Rheum Dis 66 2 4 17178757 1:STN:280:DC%2BD28jjvFCktg%3D%3D
19. PD Delmas HK Genant GG Crans JL Stock M Wong E Siris JD Adachi 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 522 32 14555255 1:STN:280:DC%2BD3svnslSgsw%3D%3D
20. DM Black S Boonen J Cauley P Delmas R Eastell I Reid T Rosario-Jansen J Caminis J Zhang H Hu S Cummings 2006 Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial J Bone Miner Res 21 S16
21. SR Cummings MJ San MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutilek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 65 19671655 1:CAS:528:DC%2BD1MXhtVWls7nF
22. JT Schousboe T Vokes SB Broy L Ferrar F McKiernan C Roux N Binkley 2008 Vertebral fracture assessment: the 2007 ISCD official positions J Clin Densitom 11 92 108 18442755
23. PD Delmas L van de Langerijt NB Watts R Eastell H Genant A Grauer DL Cahall 2005 Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study J Bone Miner Res 20 557 63 15765173
24. SJ Gallacher AP Gallagher C McQuillian PJ Mitchell T Dixon 2007 The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures Osteoporos Int 18 185 92 17109062 1:STN:280:DC%2BD2s%2FitVWlsw%3D%3D
25. JC Netelenbos WF Lems PP Geusens HJ Verhaar AJ Boermans MM Boomsma PG Mulder SE Papapoulos 2009 Spine radiographs to improve the identification of women at high risk for fractures Osteoporos Int 20 1347 52 19039511 1:STN:280:DC%2BD1MvnsVGjsQ%3D%3D
26. TP van Staa P Geusens HA Pols C de Laet HG Leufkens C Cooper 2005 A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids QJM 98 191 8 15728400
27. K Lippuner H Johansson JA Kanis R Rizzoli 2010 FRAX assessment of osteoporotic fracture probability in Switzerland Osteoporos Int 21 381 9 19517155 1:STN:280:DC%2BC3c%2FovFCqsw%3D%3D
28. C Tannenbaum J Clark K Schwartzman S Wallenstein R Lapinski D Meier M Luckey 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women J Clin Endocrinol Metab 87 4431 7 12364413 1:CAS:528:DC%2BD38XnvFCkurw%3D
29. F Saad JD Adachi JP Brown LA Canning KA Gelmon RG Josse KI Pritchard 2008 Cancer treatment-induced bone loss in breast and prostate cancer J Clin Oncol 26 5465 76 18955443
30. ES Orwoll L Bevan KR Phipps 2000 Determinants of bone mineral density in older men Osteoporos Int 11 815 21 11199184 1:STN:280:DC%2BD3M7isV2nsA%3D%3D
31. NH Bjarnason C Christiansen 2000 The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women J Clin Endocrinol Metab 85 590 6 10690860 1:CAS:528:DC%2BD3cXhtlyhtb0%3D
32. SR Cummings 1998 Prevention of hip fractures in older women: a population-based perspective Osteoporos Int 8 Suppl 1 S8 12 9682790
33. CH Chesnut III 1993 Bone mass and exercise. [Review] [17 refs] Am J Med 95 34S 6 8256792
34. CH Turner AG Robling 2004 Exercise as an anabolic stimulus for bone. [Review] [89 refs] Curr Pharm Des 10 2629 41 15320750 1:CAS:528: DC%2BD2cXlslejsr8%3D
35. KM Davies PH Pearson CA Huseman NG Greger DK Kimmel RR Recker 1990 Reduced bone mineral in patients with eating disorders Bone 11 143 7 2390371 1:STN:280:DyaK3czlvFehtQ%3D%3D
36. P Vestergaard C Emborg RK Stoving C Hagen L Mosekilde K Brixen 2003 Patients with eating disorders. A high-risk group for fractures Orthop Nurs 22 325 31 14595992
37. BL Riggs 2003 Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. [Review] [41 refs] J Cell Biochem 88 209 15 12520516 1:CAS:528:DC%2BD3sXntlymuw%3D%3D
38. NO Kuchuk NM van Schoor SM Pluijm A Chines P Lips 2009 Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective J Bone Miner Res 24 693 701 19049341 1:CAS:528:DC%2BD1MXksF2ks7Y%3D
39. HA Bischoff-Ferrari U Can HB Staehelin A Platz J Henschkowski BA Michel B wson-Hughes R Theiler 2008 Severe vitamin D deficiency in Swiss hip fracture patients Bone 42 597 602 18180211 1:CAS:528:DC%2BD1cXitVOmurc%3D
40. MC Chapuy AM Schott P Garnero D Hans PD Delmas PJ Meunier 1996 Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS study group J Clin Endocrinol Metabol 81 1129 33 1:CAS:528:DyaK28Xhs1agsbY%3D
41. H Glerup K Mikkelsen L Poulsen E Hass S Overbeck H Andersen P Charles EF Eriksen 2000 Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement Calcif Tissue Int 66 419 24 10821877 1:CAS:528:DC%2BD3cXksVSjsLs%3D
42. HA Bischoff-Ferrari WC Willett JB Wong E Giovannucci T Dietrich B wson-Hughes 2005 Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials JAMA 293 2257 64 15886381 1:CAS:528:DC%2BD2MXktFOntb8%3D
43. HA Bischoff-Ferrari B wson-Hughes WC Willett HB Staehelin MG Bazemore RY Zee JB Wong 2004 Effect of Vitamin D on falls: a meta-analysis JAMA 291 1999 2006 15113819 1:CAS:528:DC%2BD2cXjs1aisr0%3D
44. GJ Izaks 2007 Fracture prevention with vitamin D supplementation: considering the inconsistent results BMC Musculoskelet Disord 8 26 17349055
45. Bischoff-Ferrari H, et al. Effects of extended physiotherapy and high dose vitamin D on falls and morbiidy after hip fracture. Arch Intern Med. 2010;170(9):813-20.
46. S Boonen P Lips R Bouillon HA Bischoff-Ferrari D Vanderschueren P Haentjens 2007 Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials J Clin Endocrinol Metab 92 1415 23 17264183 1:CAS:528:DC%2BD2sXksVSrt7k%3D
47. MJ Bolland PA Barber RN Doughty B Mason A Horne R Ames GD Gamble A Grey IR Reid 2008 Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial BMJ 336 262 6 18198394 1:CAS:528:DC%2BD1cXjtlyru7g%3D
48. IR Reid R Ames B Mason HE Reid CJ Bacon MJ Bolland GD Gamble A Grey A Horne 2008 Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men Arch Intern Med 168 2276 82 19001206 1:CAS:528:DC%2BD1cXhsVKjtL7M
49. RP Heaney 2005 The Vitamin D requirement in health and disease J Steroid Biochem Mol Biol 97 13 9 16026981 1:CAS:528:DC%2BD2MXhtFyks7vN
50. Gillespie LD, Robertson MC, Gillespie WJ, Lamb SE, Gates S, Cumming RG, Rowe BH. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2009:CD007146.
51. L Forsen C Arstad S Sandvig A Schuller U Roed AJ Sogaard 2003 Prevention of hip fracture by external hip protectors: an intervention in 17 nursing homes in two municipalities in Norway Scand J Public Health 31 261 6 15099031
52. G Meyer A Warnke R Bender I Muhlhauser 2003 Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial BMJ 326 76 12521969
53. ID Cameron J Venman SE Kurrle K Lockwood C Birks RG Cumming S Quine G Bashford 2001 Hip protectors in aged-care facilities: a randomized trial of use by individual higher-risk residents Age Ageing 30 477 81 11742776 1:STN:280:DC%2BD38%2FnsVOhug%3D%3D
54. PD O'Halloran LJ Murray GW Cran L Dunlop G Kernohan TR Beringer 2005 The effect of type of hip protector and resident characteristics on adherence to use of hip protectors in nursing and residential homes-an exploratory study Int J Nurs Stud 42 387 97 15847901
55. EF Eriksen SF Hodgson R Eastell SL Cedel WM O'Fallon BL Riggs 1990 Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels.[see comment] J Bone Miner Res 5 311 9 2343771 1:STN:280:DyaK3c3mtFGhtQ%3D%3D
56. BL Riggs AM Parfitt 2005 Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. [Review] [63 refs] J Bone Miner Res 20 177 84 15647810 1:CAS:528: DC%2BD2MXhsFarsr8%3D
57. Delmas P, Munoz F, Black D, Cosman F, Boonen S, Watts N, Kendler D, Eriksen E, Mesenbrink P, Eastell R. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009.
58. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group.[see comment] Lancet 348 1535 41 8950879 1:CAS:528:DyaK2sXisFCktQ%3D%3D
59. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut III J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.[see comment] JAMA 282 1344 52 10527181 1:CAS:528:DyaK1MXmvFansr0%3D
60. Y Jiang JJ Zhao BH Mitlak O Wang HK Genant EF Eriksen 2003 Recombinant human parathyroid hormone [1-28] [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 1932 41 14606504 1:CAS:528:DC%2BD3sXptVyiu74%3D
61. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.[see comment] N Engl J Med 344 1434 41 11346808 1:CAS:528:DC%2BD3MXktVSgsbw%3D
62. EF Eriksen DS Colvard NJ Berg ML Graham KG Mann TC Spelsberg BL Riggs 1988 Evidence of estrogen receptors in normal human osteoblast-like cells Science 241 84 6 3388021 1:CAS:528:DyaL1cXks1Oitr8%3D
63. MJ Oursler P Osdoby J Pyfferoen BL Riggs TC Spelsberg 1991 Avian osteoclasts as estrogen target cells Proc Natl Acad Sci USA 88 6613 7 1907373 1:CAS:528:DyaK3MXlt1Omtbs%3D
64. EF Eriksen B Langdahl A Vesterby J Rungby M Kassem 1999 Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women J Bone Miner Res 14 1217 21 10404024 1:CAS:528:DyaK1MXkvVyjsbg%3D
65. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 321 33 12117397 1:CAS:528:DC%2BD38Xltlegs7k%3D
66. The womens health initiative steering committee effects of conuated equine estrogen in posstmenopausal women with hysterectomy: the womens health initiative randomized controlled trial. JAMA [serial online].
67. HD Nelson M Helfand SH Woolf JD Allan 2002 Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 137 529 41 12230356
68. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.[see comment][erratum appears in JAMA 1999 Dec 8;282(22):2124] JAMA 282 637 45 10517716 1:CAS:528:DyaK1MXlvVKqurg%3D
69. SR Cummings S Eckert KA Krueger D Grady TJ Powles JA Cauley L Norton T Nickelsen NH Bjarnason M Morrow ME Lippman D Black JE Glusman A Costa VC Jordan 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 2189 97 10376571 1:CAS:528:DyaK1MXktFGitL0%3D
70. JA Cauley L Norton ME Lippman S Eckert KA Krueger DW Purdie J Farrerons A Karasik D Mellstrom KW Ng JJ Stepan TJ Powles M Morrow A Costa SL Silfen EL Walls H Schmitt DB Muchmore VC Jordan LG Ste-Marie 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 65 125 34 11261828 1:CAS:528:DC%2BD3MXisVCjur4%3D
71. Vogel VG, Constantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41.
72. SR Cummings K Ensrud PD Delmas AZ LaCroix S Vukicevic DM Reid S Goldstein U Sriram A Lee J Thompson RA Armstrong DD Thompson T Powles J Zanchetta D Kendler P Neven R Eastell 2010 Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 686 96 20181970 1:CAS:528:DC%2BC3cXisFOqsro%3D
73. MR McClung E Siris S Cummings M Bolognese M Ettinger A Moffett R Emkey W Day V Somayaji A Lee 2006 Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Menopause 13 377 86 16735934
74. S Khosla LJ Melton III BL Riggs 2002 Clinical review 144: estrogen and the male skeleton. [Review] [54 refs] J Clin Endocrinol Metab 87 1443 50 11932262 1:CAS:528:DC%2BD38XivFKlsbw%3D
75. CG Carlsen TH Soerensen EF Eriksen 2000 Prevalence of low serum estradiol levels in male osteoporosis Osteoporos Int 11 697 701 11095173 1:CAS:528:DC%2BD3cXnsVegtbo%3D
76. FH Anderson RM Francis RT Peaston HJ Wastell 1997 Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months' treatment on markers of bone formation and resorption J Bone Miner Res 12 472 8 9076591 1:CAS:528:DyaK2sXitlKmur4%3D
77. S Bhasin GR Cunningham FJ Hayes AM Matsumoto PJ Snyder RS Swerdloff VM Montori 2006 Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline J Clin Endocrinol Metab 91 1995 2010 16720669 1:CAS:528:DC%2BD28XlvVChu7g%3D
78. JK Amory NB Watts KA Easley PR Sutton BD Anawalt AM Matsumoto WJ Bremner JL Tenover 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone J Clin Endocrinol Metab 89 503 10 14764753 1:CAS:528:DC%2BD2cXhsFOjsrw%3D
79. A Morgentaler 2009 Rapidly shifting concepts regarding androgens and prostate cancer Sci World J 9 685 90 1:CAS:528:DC%2BC3cXhsVSjtr8%3D
80. A Morgentaler 2006 Testosterone replacement therapy and prostate risks: where's the beef? Can J Urol 13 Suppl 1 40 3 16526980
81. K Overgaard MA Hansen SB Jensen C Christiansen 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study BMJ 305 556 61 1393035 1:STN:280:DyaK3s%2Fgs1eksQ%3D%3D
82. Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-76
83. Chesnut CH, 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005;20(9):1548-61.
84. MJ Rogers JC Frith SP Luckman FP Coxon HL Benford J Monkkonen S Auriola KM Chilton RG Russell 1999 Molecular mechanisms of action of bisphosphonates. [Review] [69 refs] Bone 24 73S 9 10321934 1:CAS:528:DyaK1MXjtVGitLc%3D
85. PJ Meunier M Arlot P Chavassieux AJ Yates 1999 The effects of alendronate on bone turnover and bone quality Int J Clin Pract Suppl 101 14 7 12669736 1:CAS:528:DyaK1MXjs1ansLY%3D
86. EF Eriksen F Melsen E Sod I Barton A Chines 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 31 620 5 12477578 1:CAS:528:DC%2BD38XptlGisrk%3D
87. T Steiniche C Hasling P Charles EF Eriksen F Melsen L Mosekilde 1991 The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime Bone 12 155 63 1910957 1:STN:280:DyaK38%2FgtV2mtA%3D%3D
88. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): a randomized trial JAMA 296 2927 38 17190893 1:CAS:528:DC%2BD2sXnvVGh
89. DC Bauer D Black K Ensrud D Thompson M Hochberg M Nevitt T Musliner D Freedholm 2000 Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial Arch Intern Med 160 517 25 10695692 1:CAS:528:DC%2BD3cXhvFGhuro%3D
90. PC de Groen DF Lubbe LJ Hirsch A Daifotis W Stephenson D Freedholm S Pryor-Tillotson MJ Seleznick H Pinkas KK Wang 1996 Esophagitis associated with the use of alendronate N Engl J Med 335 1016 21 8793925
91. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008.
92. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg RF Gagel V Gilsanz T Guise S Koka LK McCauley J McGowan MD Mckee S Mohla DG Pendrys LG Raisz SL Ruggiero DM Shafer L Shum SL Silverman CH Van Poznak N Watts SB Woo E Shane 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 91 17663640
93. D Felsenberg 2006 Osteonecrosis of the jaw-a potential adverse effect of bisphosphonate treatment Nat Clin Pract Endocrinol Metabol 2 662 3
94. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 6 18354114 1:CAS:528:DC%2BD1cXjvVarsb8%3D
95. B Abrahamsen P Eiken 2008 Subtrochanteric femur fracture in patients treated with oral bisphosphonates: a national register study Calcif Tissue Int 82 S209
96. HA Pols D Felsenberg DA Hanley J Stepan M Munoz-Torres TJ Wilkin G Qin-sheng AM Galich K Vandormael AJ Yates B Stych 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporos Int 9 461 8 10550467 1:CAS:528:DyaK1MXkt1CktrY%3D
97. T Schnitzer HG Bone G Crepaldi S Adami M McClung D Kiel D Felsenberg RR Recker RP Tonino C Roux A Pinchera AJ Foldes SL Greenspan MA Levine R Emkey AC Santora A Kaur DE Thompson J Yates JJ Orloff 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging Clin Exp Res 12 1 12 1:CAS:528:DC%2BD3cXitVCns7g%3D
98. Schwartz AV, Bauer DC, Cauley JA, Ensrud KE, Palermo L, Cummings SR, Black DM. Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX Trial (abstract)., 22 ed. 2007;p. S1057.
99. L Mortensen P Charles PJ Bekker J DiGennaro CC Johnston Jr 1998 Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up J Clin Endocrinol Metab 83 396 402 9467547 1:CAS:528:DyaK1cXhtVSmsro%3D
100. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 10663363 1:CAS:528:DC%2BD3cXhvFGgsr0%3D
101. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.[see comment] N Engl J Med 344 333 40 11172164 1:CAS:528:DC%2BD3MXht1Wlu7g%3D
102. BJ Riis J Ise T von Stein Y Bagger C Christiansen 2001 Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis J Bone Miner Res 16 1871 8 11585352 1:CAS:528:DC%2BD3MXnsVKqtLo%3D
103. CH Chesnut MP Ettinger PD Miller DJ Baylink R Emkey ST Harris RD Wasnich NB Watts RC Schimmer RR Recker 2005 Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE Curr Med Res Opin 21 391 401 15811208 1:CAS:528: DC%2BD2MXktl2hsrw%3D
104. S Boonen DE Sellmeyer K Lippuner A Orlov-Morozov K Abrams P Mesenbrink EF Eriksen PD Miller 2008 Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women Kidney Int 74 641 8 18509324 1:CAS:528:DC%2BD1cXpvVaiurY%3D
105. EF Eriksen 2002 Primary hyperparathyroidism: lessons from bone histomorphometry. [Review] [19 refs] J Bone Miner Res 17 Suppl 2 N95 7 12412784
106. H Dobnig RT Turner 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats Endocrinology 138 4607 12 9348185 1:CAS:528:DyaK2sXmslGrsbk%3D
107. E Orwoll W Scheele S Paul S Adami U Syversen A ez-Perez JM Kaufman A Clancy G Gaich 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 9 17 12510800 1:CAS:528:DC%2BD3sXltFKmtw%3D%3D
108. MR McClung MJ San PD Miller R Civitelli F Bandeira M Omizo DW Donley GP Dalsky EF Eriksen 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 8 16087825 1:CAS:528:DC%2BD2MXpslGgs7c%3D
109. JR Zanchetta CE Bogado JL Ferretti O Wang MG Wilson M Sato GA Gaich GP Dalsky SL Myers 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis J Bone Miner Res 18 539 43 12619939 1:CAS:528:DC%2BD3sXitVyrsb0%3D
110. R Lindsay P Miller G Pohl EV Glass P Chen JH Krege 2009 Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis Osteoporos Int 20 943 8 18923884 1:CAS:528: DC%2BD1MXls12kt7w%3D
111. SL Greenspan HG Bone MP Ettinger DA Hanley R Lindsay JR Zanchetta CM Blosch AL Mathisen SA Morris TB Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 39 17339618
112. RS Rittmaster M Bolognese MP Ettinger DA Hanley AB Hodsman DL Kendler CJ Rosen 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.[see comment] J Clin Endocrinol Metab 85 2129 34 10852440 1:CAS:528:DC%2BD3cXlsVequr0%3D
113. F Cosman J Nieves L Woelfert C Formica S Gordon V Shen R Lindsay 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 925 31 11341338 1:CAS:528:DC%2BD3MXjs1Wjuro%3D
114. R Lindsay WH Scheele R Neer G Pohl S Adami C Mautalen JY Reginster JJ Stepan SL Myers BH Mitlak 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Int Med 164 2024 30
115. Cosman F, Eriksen EF, Recknor C, Miller P, Greenspan S, Papanastasiou P, Rao HV, Gasser J, Bucci-Recthweg C, Boonen S. Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis. J Bone Miner Res. 2009.
116. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, varo-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San MJ, Bone HG. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009:1-34.
117. Amgen press release. http://wwwext.amgen.com/media/media-pr-detailjsp? year=2009&releaseID=1305355 [serial online].
118. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh EM Lemmel S Pors-Nielsen R Rizzoli HK Genant JY Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.[see comment] N Engl J Med 350 459 68 14749454 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D
119. JY Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos JP Devogelaer MD Curiel A Sawicki S Goemaere OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 22 15728210 1:CAS:528: DC%2BD2MXkt1Wgt78%3D
120. E Seeman B Vellas C Benhamou JP Aquino J Semler JM Kaufman K Hoszowski AR Varela C Fiore K Brixen JY Reginster S Boonen 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older J Bone Miner Res 21 1113 20 16813532 1:CAS:528:DC%2BD28XntlWqu7k%3D